Further studies assessing the impact of LSALT treatment on neutrophil recruitment and potentially concomitant CD8+ T cell exclusion in CRC or in other cancers could lead to a viable therapeutic to be combined with ICI. The gene discussed is CD8A; the disease is cancer.